IPO registrations (S-1, F-1) · Registrants

CHINOOK THERAPEUTICS, INC.

SEC CIK
1435049 · filings on EDGAR ↗
Name on the registration
ADURO BIOTECH, INC.
Former names
ADURO BIOTECH, INC. (2011–2020); ADURO BIOTECH (2008–2011)
Registration
Form S-1, first filed 2015-03-11, last 2015-04-14; 1 initial registration, 2 amendments
Outcome
Final prospectus filed 2015-04-15; declared effective 2015-04-14
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
400 FAIRVIEW AVENUE NORTH, SUITE 900, Seattle, WA 98109
EDGAR entity type
operating
Insiders and CEO pay
CHINOOK THERAPEUTICS, INC. on the corporate pages

Offering terms

Final price
$17.00 per share (424B4 filed 2015-04-15, an initial public offering)
Shares sold
7,000,000
Gross proceeds
$119,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol ADRO
Lead underwriters
Merrill Lynch; Leerink Partners (2,275,000 shares)
Syndicate
BofA Securities; William Blair (1,225,000); Canaccord Genuity (700,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
2015-03-11S-1S-1 (registration)ADURO BIOTECH, INC.0001193125-15-087572 ↗
2015-04-06S-1/AS-1/A (amendment)ADURO BIOTECH, INC.0001193125-15-119482 ↗
2015-04-14S-1/AS-1/A (amendment)ADURO BIOTECH, INC.0001193125-15-128339 ↗
2015-04-14EFFECTEFFECT (declared effective)ADURO BIOTECH, INC.9999999995-15-000865 ↗
2015-04-15424B4424B4 (final prospectus)ADURO BIOTECH, INC.0001193125-15-131360 ↗
2016-05-09EFFECTEFFECT (declared effective)ADURO BIOTECH, INC.9999999995-16-004590 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2015-04-14S-1/Aregistration statement$17.007,000,000$119,000,000Nasdaq ADRO6primary document; price sentence, shares headline, proceeds computed, underwriting table 1, cover names 4document ↗
2015-04-15424B4final prospectus$17.007,000,000$119,000,000Nasdaq ADRO5primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Brockstedt Dirk G.OfficerEVP of Research and Dev.; Sr. VP of Research and Dev.262015–2018
Chan GeraldDirector52015–2018
Dubensky Thomas W.OfficerChief Scientific Officer222015–2017
Greenman William MarinerDirector162015–2023
Haghighat RossDirector162015–2023
ISAACS STEPHEN TDirector,OfficerPresident and CEO472015–2020
Lew JenniferOfficerChief Financial Officer; Sr. Vice President of Finance282015–2019
MCCORMICK FRANKDirector52015–2018
Morningside Venture (VI) Investments LtdTenPercentOwner42015–2018
OBrien Stephanie MonaghanDirector82015–2020
Rogers John E. and Lois A.TenPercentOwner42015
SCHAFER GREGORY WOfficerChief Operating Officer232015–2018
Ultimate Keen LtdTenPercentOwner22015
SHERWIN STEPHEN ADirector72015–2020
Templeman BlaineOfficerChief Legal Officer; Executive VP, General Counsel; See Remarks272015–2020
Sacks NatalieOfficerChief Medical Officer92016–2018
van Elsas AndreaOfficerChief Scientific Officer212017–2020
Hoth Daniel Floyd JROfficerInterim Chief Medical Officer12018
Ferber CelesteOfficerSVP, GC and Secretary92019–2020
Mack David HenryDirector42019–2020
KARBE FRANKDirector52019–2020
Nuyten Dimitry SAOfficerChief Medical Officer52019–2020
WELCH JAMES HOfficerSee Remarks22019
Kachioff William GOfficerInterim CFO; See Remarks22020
AKKARAJU SRINIVASDirector92020–2023
DOBMEIER ERICDirector,OfficerPresident, CEO232020–2023
Frohlich TomOfficerChief Business Officer; Chief Operating Officer172020–2023
Glicklich AlanOfficerChief Medical Officer62020–2022
GRIFFIN MICHELLE RENEEDirector62020–2023
Jerel DavisDirector; Director,TenPercentOwner152020–2023
King Andrew JamesOfficerChief Scientific Officer; Head of Renal Discovery212020–2023
Thomas DolcaDirector72020–2023
Versant Venture Capital VII, L.P.TenPercentOwner42020–2022
Versant Voyageurs I, L.P.TenPercentOwner42020–2022
Versant Voyageurs I Parallel, L.P.TenPercentOwner42020–2022
BJERKHOLT ERICOfficerChief Financial Officer102020–2023
Krishnan MaheshDirector42022–2023
Oxtoby AndrewOfficerChief Commercial Officer32023
Azelby RobertDirector32023

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2015-01-05ADURO BIOTECH, INC.Biotechnology$51,388,002$51,388,002281
2014-06-13ADURO BIOTECH, INC.Biotechnology$40,602,333$40,602,333251

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Form D issuerADURO BIOTECH, INC.CAForm D private offeringsCIK (EXACT)
Patent assigneeChinook Therapeutics, Inc.WAPatents (USPTO)name and state
SEC filerCHINOOK THERAPEUTICS, INC.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerCHINOOK THERAPEUTICS, INC.WATrademarks (USPTO)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, WA first:

More with this interest.

In other datasets, the same topic (Health) in WA:

Interests: Pharmaceutical Preparations · Health